Table 1 Demographic and clinical features of 485 surveyed patients with thyroid cancer
All (n = 485) | Females (n = 429) | Males (n = 56) | |
|---|---|---|---|
Age, yr | 43.4 ± 9.9 | 43.0 ± 9.7 | 46.4 ± 10.6* |
Age at diagnosis, yr | 37.5 ± 10.3 | 37.1 ± 10.1 | 41.0 ± 11.0* |
Time of evolution, yr | 4 (2–7) | 4 (2–8) | 4 (2–7) |
Education | |||
Primary or secondary | 244 (50.3) | 216 (50.3) | 28 (50.0) |
University | 241 (49.7) | 213 (49.7) | 28 (50.0) |
Tumor type | |||
Papillary | 382 (78.8) | 338 (78.8) | 44 (78.6) |
Follicular | 40 (8.2) | 37 (8.6) | 3 (5.4) |
Medullary | 27 (5.6) | 21 (4.9) | 6 (10.7) |
Other | 18 (3.7) | 17 (4.0) | 1 (1.8) |
Unknown | 18 (3.7) | 16 (3.7) | 2 (3.6) |
Tumor extension at diagnosis | |||
Thyroid | 247 (50.9) | 221 (51.5) | 26 (46.4) |
Thyroid and lymph nodes | 206 (42.5) | 181 (42.2) | 25 (44.6) |
Distant metastases | 23 (4.7) | 19 (4.4) | 4 (7.1) |
Unknown | 9 (1.9) | 8 (1.9) | 1 (1.8) |
Type of hospital | |||
Private | 81 (16.7) | 67 (15.6) | 14 (25.0) |
Public | 367 (75.7) | 328 (76.5) | 39 (69.6) |
Both | 37 (7.6) | 34 (7.9) | 3 (5.4) |
Radioiodine | |||
No | 91 (18.8) | 79 (18.4) | 12 (21.4) |
1 dose | 269 (55.5) | 245 (57.1) | 24 (42.9) |
2 doses | 92 (19.0) | 78 (18.2) | 14 (25.0) |
More than 2 doses | 31 (6.4) | 25 (5.8) | 6 (10.7) |
Unknown | 2 (0.4) | 2 (0.5) | 0 (0) |
Medications | |||
Levothyroxine | 481 (99.2) | 425 (99.1) | 56 (100) |
Calcium salts | 150 (30.9) | 138 (32.2) | 12 (21.4) |
Active vitamin D | 81 (16.7) | 75 (17.5) | 6 (10.7) |
Tyrosine-kinase inhibitors | 12 (2.5) | 7 (1.6) | 5 (8.9)** |
Disease situation at the time of survey | |||
Cured | 252 (52.0) | 233 (54.3) | 19 (33.9)** |
Not cured, no need of therapy | 175 (36.1) | 150 (35.0) | 25 (44.6) |
Not cured, in need of therapy | 58 (12.0) | 46 (10.7) | 12 (21.4) |
Chronic complications | |||
Local discomfort or pain | 186 (38.4) | 158 (36.8) | 28 (50.0) |
Hypoparathyroidism | 152 (31.3) | 140 (32.6) | 12 (21.4) |
Dry mouth | 148 (30.5) | 132 (30.8) | 16 (28.6) |
Dysphonia | 146 (30.1) | 123 (28.7) | 23 (41.1) |
Neck mobility problems | 92 (19.0) | 80 (18.6) | 12 (21.4) |
Dysgeusia | 62 (12.8) | 58 (13.5) | 4 (7.1) |
Other | 156 (32.2) | 134 (31.2) | 22 (39.3) |